Elicio says Phase 2 AMPLIFY-7P pancreatic cancer data for ELI-002 7P earns late-breaking oral slot at ESMO 2026

Bitget2026/09/24 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elicio Therapeutics set new Phase 2 AMPLIFY-7P analyses of ELI-002 7P for an Oct. 23, 2026 oral presentation at ESMO.
Prior results showed the trial missed its main disease-free survival goal in the overall study population.
New pre-specified analyses aim to clarify clinical and biological activity in resected KRAS-mutant pancreatic cancer.
Readout is expected to shape a revised Phase 3 strategy in the adjuvant setting.
AMPLIFY-7P enrolled 144 patients across 24 U.S. sites, comparing ELI-002 7P versus observation post-standard therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9833006) on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elicio says Phase 2 AMPLIFY-7P pancreatic cancer data for ELI-002 7P earns late-breaking oral slot at ESMO 2026

You may also like

Crypto prices